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PHARMACOKINETICS AND
DRUG DISPOSITION
Ethanol and production of the hepatotoxic
metabolite of acetaminophen in healthy adults
Background: Recent case reports suggest that consumption of ethanol may increase the risk of liver injury
induced by acetaminophen (INN, paracetamol). However, this possibility is at odds with previous clinical
studies that showed that acute ethanol ingestion could protect against hepatotoxicity by inhibiting CYP-medi-
ated acetaminophen oxidation. We tested the hypothesis that ethanol ingestion can increase susceptibility to
acetaminophen toxicity if acetaminophen ingestion occurs shortly after ethanol is cleared from the body.
Methods: Ten healthy volunteers each received a 6-hour intravenous infusion of ethanol (to achieve a blood
concentration of 100 mg/dL ethanol) or 5% dextrose in water, administered in random order. Acet-
aminophen (500 mg) was ingested 8 hours after the end of the infusion. Blood and urine were collected
for assessment of formation of N-acetyl-p-benzoquinone imine (NAPQI), the hepatotoxic metabolite of
acetaminophen.
Results: Mean NAPQI formation was enhanced by 22% (range, 2% to 38%; P < .03) when the acetaminophen
dose was given after an ethanol infusion, compared with after 5% dextrose in water infusion. This mean
increase was similar in magnitude to that predicted by a mathematical model describing the induction of
CYP2E1, the main enzyme catalyzing NAPQI formation, by a mechanism of enzyme stabilization.
Conclusions: Consumption of up to one 750-mL bottle of wine, six 12-ounce cans of beer, or 9 ounces of
80-proof liquor over the course of a single evening modestly increases the fraction of an acetaminophen
dose converted to its toxic metabolite, NAPQI, when acetaminophen is ingested soon after ethanol has
been cleared from the body. This change in acetaminophen metabolism may present an incremental increase
in the risk of acetaminophen hepatotoxicity. (Clin Pharmacol Ther 2000;67:591-9.)
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It is now generally accepted that after an overdose
of acetaminophen (INN, paracetamol), persons with
chronic alcoholism are at increased risk of acet-
aminophen-induced hepatotoxicity.1-4 This susceptibil-
ity may in part relate to the observation that persons
with chronic alcoholism have increased activity of
CYP2E1,5,6 the major liver enzyme that produces
N-acetyl-p-benzoquinone imine (NAPQI) from acet-
aminophen.7-10 NAPQI is a chemically reactive molecule
that can interact with hepatocellular proteins and other
molecules, triggering a cascade of intracellular changes
that culminate in cell death.11 After currently recom-
mended doses of acetaminophen (up to 4 g daily),
hepatic NAPQI formation should be of no clinical con-
sequence because only 4% to 10% of the dose is cleared
from the body by this pathway and because the metabo-
lite is rapidly detoxified by conjugation with glutathione
and excreted into the urine as several secondary thioether
metabolites.12 However, an increased level of CYP2E1
activity may result in the conversion of a greater propor-
tion of the ingested dose to NAPQI, increasing suscepti-
bility to acetaminophen-induced liver toxicity.
There has been little reason to suspect that moderate
drinkers in good general health are at increased risk of
acetaminophen toxicity. However, this is now a contro-
versial issue. In a recent report of 69 patients in whom
acetaminophen hepatotoxicity developed after taking
acetaminophen,3 nine individuals reported daily alco-
hol ingestion of less than or equal to 60 g (approxi-
mately 7 ounces of 80-proof liquor). Five of these also
reported acetaminophen ingestion of 4 g or less daily.
There are currently no scientific data to support an
association between ethanol and increased susceptibil-
ity to acetaminophen toxicity outside the population of
persons with chronic alcoholism. Indeed, previous stud-
ies have shown that NAPQI formation from acet-
aminophen is actually reduced in healthy volunteers who
were given ethanol.13,14 This observation is consistent
with animal studies that showed that ethanol exposure
can protect against acetaminophen-induced liver toxic-
ity.15,16 However, in these studies acetaminophen was
administrated when ethanol was still present in the
body. Ethanol is both a substrate and an inhibitor of
CYP2E1.17 It is well-established that ethanol and other
CYP2E1 substrates and inhibitors (ligands) induce the
enzyme but that enhanced catalytic activity is only
observed once the ligand is eliminated.18-22 Therefore
any increase in NAPQI formation caused by ethanol
ingestion may only occur after ethanol is cleared from
the body.
To investigate this possibility, we administered
ethanol intravenously to healthy volunteers for 6 hours,
mimicking the consumption of a standard 750-mL bot-
tle of wine, six 12-ounce cans of beer, or 9 ounces of
80-proof liquor. The production of NAPQI was deter-
mined just after ethanol was cleared from the body. The
results we obtained were consistent with those pre-
dicted by a recently reported mathematical model for
induction of CYP2E1 activity.22
MATERIAL AND METHODS
Human subjects. Subjects were studied in the Gen-
eral Clinical Research Center at the University of
Michigan Medical Center (Ann Arbor, Mich) with Insti-
tutional Review Board approval and written informed
consent. They were between 21 and 50 years old, were
in good health (history and physical examination), were
nonsmokers, were without biochemical evidence of
renal or hepatic dysfunction, and were not pregnant.
Abstainers or individuals who admitted to consuming
alcohol on more than an occasional basis (once a week)
were excluded. Subjects were identified through flyers
posted around the University of Michigan campus and
were paid for their participation.
Study design. Five men and five women were
enrolled in an open-label, randomized crossover study
with two treatment phases. In the first phase, 10%
ethanol (wt/vol) in 5% dextrose in water (D5W) was
infused; in the second phase, only D5W was infused.
Subjects were instructed to refrain from drinking alco-
holic beverages and from taking medications that con-
tained acetaminophen for the duration of the study.
Ethanol or D5W infusions were started at 6 PM. Sub-
jects were instructed to fast between 12 noon and the
beginning of the infusion, at which time they were fed.
Subjects were randomly assigned to receive either
ethanol or D5W infusion in the first session and were
crossed over to the alternate treatment at least 1 week
later. Ethanol administration began with a bolus infusion
of 7.5 mL/kg of 10% ethanol in D5W over 30 minutes.
A maintenance ethanol (10% in D5W) infusion rate of
1.39 mL/kg/hour was started at the same time and con-
tinued for 6 hours.23 Blood ethanol levels were obtained
frequently and when found to be greater than 150 mg/dL
the ethanol infusion was stopped for 30 minutes and then
resumed at 75% of the previous rate. There were two
instances in which this occurred (subjects 2 and 4). When
D5W was administered, it was given as a bolus and main-
tenance infusion at the same initial rates used for the
ethanol infusion. Blood samples drawn at 0 and 6 hours
confirmed the absence of ethanol in all subjects.
Acetaminophen (500-mg oral tablet) was adminis-
tered 8 hours (8 AM) after the end of the ethanol or D5W
infusion. Blood was collected serially for 12 hours after
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acetaminophen ingestion. Plasma was separated and
stored at –20°C until analysis. Urine was collected for
24 hours after acetaminophen ingestion and maintained
at 4°C over 3 g L-ascorbic acid.24 Total volume was
recorded and an aliquot was stored at –80°C until analy-
sis. Acetaminophen in plasma and urine and its metabo-
lites in urine were assayed by HPLC.19 Blood ethanol
was quantified by an enzymatic assay (Vitros Chem-
istry Products, Rochester, NY).
Pharmacokinetic analyses. Total area under the
acetaminophen plasma concentration–time curve
(AUC) was calculated by WinNonlin (Scientific Con-
sulting, Inc, Cary, NC). Plasma clearance (CL) of acet-
aminophen was calculated as Dose/AUC. The fraction
of dose accounted for in urine as acetaminophen and
the various metabolites was 94.1% (4.7%) and 91.9%
(3.4%) for the D5W and ethanol phases, respectively.
The fraction metabolized (fm) is the amount of each
metabolite recovered in urine divided by the acetamin-
ophen dose. Recovery of all thioether metabolites
(derived from the conjugation of NAPQI with glu-
tathione) was summed for the calculation of NAPQI fm.
Metabolite formation clearance (CLf, the fraction of
acetaminophen clearance accounted for by formation
of the respective metabolite) was calculated as the prod-
uct of fm and CL. Pharmacokinetic computations and
analyses of blood and urine were performed by inves-
tigators blinded to the treatment phases.
Biostatistics. For acetaminophen pharmacokinetic
parameters, the percent difference between the D5W
and ethanol infusion phases of the study was calculated
as the value of the ethanol phase minus the D5W phase
divided by the value of the D5W phase. Results are
reported as mean (SD). Statistical significance was
determined with the Student two-tailed paired t test
(SigmaStat, Jandel Scientific Inc, San Rafael, Calif),
with α = .05.
Model simulations. A kinetic model that relates the
inhibition and induction of CYP2E1-dependent clear-
ance to substrate concentration and the substrate
Michaelis-Menten constant (Km), and the concentration
of the inhibitor-inducer and its enzyme dissociation
constant (Ki) has been described and appears to suc-
cessfully predict isoniazid induction of CYP2E1 in
humans.22 Based on experimental data,19,21 the model
includes two physical pools of CYP2E1, the first sub-
ject to both rapid (kdeg,fast) and slow degradation
(kdeg,slow) and the second in which only the slow
process operates. Synthesis of new enzyme is assumed
to occur at a constant rate (Rsyn) and adds to the first
enzyme pool. Enzyme is transferred from pool 1 to pool
2 according to a first-order rate process (ktrans). Rat
studies show that ligand stabilizes the enzyme from
degradation by the rapid process without affecting the
slower one.25-27 The model treats CYP2E1 inhibition
as competitive and provides for enzyme to accumulate
as a consequence of its stabilization through occupa-
tion of the active site by ligand:
[fu = 1/1 + (I/Ki)]
in which fu is the fraction of the enzyme pool that is
free of ligand and Ki is the equilibrium dissociation
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Fig 1. Ethanol concentration–time profiles after a 6-hour constant rate infusion. Each data point is
the mean ± SD for 10 subjects.
constant. The time course for enzyme accumulation in
pools 1 and 2 after administration of an inhibitor-
inducer (I) is described by the following:
= E0,1(kdeg,fast + ktrans) – (kdeg,slow + ktrans) –
(kdeg,fast + ktrans)
= E1 · ktrans – E2 · kdeg,slow
Assuming that the basal clearance of a substrate in the
absence of the inducer-inhibitor is described by the
single-enzyme Michaelis-Menten equation, clearance
of acetaminophen to NAPQI at time t in the presence
of the competitive inducer-inhibitor can be described
by the equation:
= 
Simulations of the effect of ethanol on NAPQI forma-
tion were conducted with use of the mean concentrations
of ethanol and acetaminophen observed in this study and
their respective Ki (16.5 mmol/L) and Km (1 mmol/L)
values for human CYP2E1. Because human CYP2E1
half-lives are not known, the simulation was performed
with fast and slow degradation half-life values (7 and 37
hours, respectively) measured directly in rats.26,27
RESULTS
All subjects completed the study without a signifi-
cant adverse event. After an initial overshoot after the
E (1 + S/Km)
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bolus ethanol infusion, blood ethanol concentration was
effectively maintained at ~100 mg/dL for the duration
of the infusion (Fig 1). Six hours after the end of the
ethanol infusion, blood ethanol concentration was
below the limit of quantitation (10 mg/dL) in seven of
10 subjects but measurable in the other three (Table I).
However, on the basis of the 6-hour concentration and
observed rates of ethanol elimination, ethanol concen-
trations in these three subjects were projected to be <10
mg/dL at the time of acetaminophen administration 2
hours later.
Examples of the acetaminophen concentration–time
profile for a subject in the study are shown in Fig 2.
Administration of ethanol had no significant effect on
acetaminophen clearance—25.3 (9.74) L/h versus 25.3
(9.72) L/h for the D5W and ethanol phases, respec-
tively. There were no major effects on the fractional
formation clearances to the sulfate and glucuronide
metabolites. Mean fractional clearances to the sulfate
metabolite were 6.09 (1.95) L/h versus 5.93 (1.93) L/h
for the D5W and ethanol phases, respectively. The mean
fractional clearances to the glucuronide metabolite
were 15.1 (7.40) L/h versus 14.3 (6.52) L/h for the D5W
and ethanol phases, respectively. These pharmacoki-
netic results were expected with selective modification
of a quantitatively minor route of elimination (ie,
NAPQI formation).
The effect of ethanol on the formation of NAPQI is
summarized in Table I. There was a significant 21.6%
(11.2%) increase in the fraction of the dose eliminated
as thioether metabolites and a 23.7% (22.2%) increase
in the formation clearance of NAPQI. All 10 subjects
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Table I. Individual urinary recovery and formation clearance of NAPQI conjugates
Ethanol (mg/dL) Total thioethers (% recovered dose) Thioether formation clearance (L/h)
Subject 5% Dextrose Change 5% Dextrose Change
No. 6 h* 12 h† in water Ethanol (%) in water Ethanol (%)
1 140 52 6.45 7.34 13.8 1.78 1.62 –8.99
2 74 Below detectable limit 4.92 6.76 37.4 1.89 2.46 30.2
3 81 Below detectable limit 9.86 12.4 25.8 2.05 2.89 41.0
4 98 Below detectable limit 6.96 8.66 24.4 1.29 1.82 41.1
5 70 Below detectable limit 5.38 6.22 15.6 2.04 2.14 4.9
6 102 21 7.97 11.0 38.0 3.10 4.90 58.1
7 78 Below detectable limit 8.82 10.1 14.5 1.91 2.21 15.7
8 80 Below detectable limit 7.27 8.59 18.2 1.36 1.46 7.35
9 120 35 11.4 14.4 26.3 1.52 2.20 44.7
10 97 Below detectable limit 5.87 5.99 2.04 1.00 1.03 3.00
Mean 94 7.49 9.15‡ 21.6 1.79 2.27‡ 23.7
SD 22 2.05 2.80 11.2 0.58 1.06 22.2
*Blood ethanol concentration 6 hours after start of infusion.
†Blood ethanol concentration 6 hours after end of infusion.
‡P < .03, comparison of ethanol versus 5% dextrose in water phases by the Student two-tailed paired t test.
showed an increase in the fraction of the acetaminophen
dose metabolized to NAPQI (Fig 3). Nine of 10 sub-
jects showed an increase in NAPQI formation clear-
ance. Both parameter changes were significant by
paired t test (P < .03).
Although CYP2E1 dominates NAPQI formation,7-9
other P450 isoforms, CYP3A4 in particular, can cat-
alyze the reaction in vitro.8,9 To exclude induction of
CYP3A4 by short-term exposure to ethanol28 as a
mechanism of enhanced NAPQI formation, a carbon
dioxide breath test measure of hepatic CYP3A activ-
ity29 was performed just before the start of each phase
of the study. Results showed no difference in CYP3A4-
dependent erythromycin metabolism between D5W and
ethanol phases [2.50% (1.02%) versus 2.47% (0.81%)
of 14C dose exhaled per hour], indicating the absence
of CYP3A4 induction by short-term ethanol infusion.
A mathematical model was used to simulate changes
in liver CYP2E1 content and catalytic activity produced
by the plasma levels of ethanol we observed in our study
(Fig 4). The simulation shows that the total amount of
CYP2E1 in the liver increases during the period of
ethanol exposure [E(t)/E0] and then declines to baseline
as ethanol is eliminated. Peak enzyme level occurs 4
hours after the end of a 6-hour ethanol infusion (100
mg/dL). However, because ethanol strongly inhibits the
catalytic activity of the enzyme, it must be almost
entirely removed from the body before inhibition is sub-
stantially reversed. The model predicts that peak capac-
ity to produce NAPQI from acetaminophen [CL(t)/CL0]
does not occur until 6 to 7 hours after the end of the
ethanol infusion and declines thereafter. As a result of
the study design, ethanol and acetaminophen concen-
trations varied little among the subjects. Therefore the
model could not account for differences in NAPQI for-
mation clearance among individuals. However, as shown
in Table II,30 the predicted peak CL(t)/CL0 (1.21) was
very similar to the observed mean value (1.24).
DISCUSSION
We found that short-term ethanol exposure in healthy
adults resulted in a statistically significant increase in
the mean production of NAPQI from a single 500-mg
acetaminophen dose. Investigators have previously
reported that there was a 67% decrease in NAPQI urine
recovery relative to control when acetaminophen was
administered just after the start of an oral ethanol dos-
ing scheme (0.6 g/kg ethanol loading dose, followed by
0.1–0.16 g/kg, hourly for 8 hours).14 However, our data
are not at odds with the published report. Because of the
biphasic nature of the ethanol-acetaminophen interac-
tion, the timing of acetaminophen ingestion is critical
to demonstrating the inductive effect of ethanol (Fig 4).
Ethanol inhibits the enzyme that dominates NAPQI pro-
duction (CYP2E1) so that increased capacity to produce
NAPQI is not evident until virtually all of the ethanol
is cleared from the body. Our data indicate that in most
individuals with a blood ethanol level at the legal limit
of intoxication (100 mg/dL), a lapse of 8 hours from the
time of last ingestion is sufficient for the transition from
inhibited to enhanced NAPQI formation.
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Fig 2. Acetaminophen concentration–time profiles from a
representative subject. Open symbols, 5% dextrose in water
(D5W) infusion; solid symbols, ethanol infusion.
Fig 3. Induction of NAPQI formation by ethanol infusion.
Each pair of data points represents the amount of NAPQI
recovered in a 24-hour urine collection from a single subject.
Acetaminophen was administered to 10 subjects 8 hours after
the end of a 6-hour D5W (control) and ethanol (100 mg/dL)
infusion. The mean recovery for each treatment group is
denoted by the horizontal bar.
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Fig 4. Simulated time course of NAPQI formation clearance and CYP2E1 enzyme ratios during
and after a 6-hour infusion that maintained a 100-mg/dL blood ethanol concentration. The enzyme
ratio (upper panel) is the CYP2E1 level predicted at any time during or after the ethanol infusion
[E(t)] divided by the basal value predicted with D5W infusion [E0]. The formation clearance ratio
(lower panel) is the clearance measured at any time during or after the ethanol infusion [CL(t)]
divided by the value obtained with D5W infusion [CL0]. The simulated curve is based on 7-hour
and 37-hour fast and slow CYP2E1 degradation half-lives.
Table II. Model simulated effect of ethanol concentration and duration of exposure on NAPQI formation
Continuous Intermittent§
6 h 48 h 200 h 200 h
Max Max Max Max
Tmax* CL(t)/CL0† Tenh‡ Tmax CL(t)/CL0 Tenh Tmax CL(t)/CL0 Tenh Tmax CL(t)/CL0 Tenh
100 mg/dL ethanol 1.24
(experimental)
100 mg/dL ethanol 6 1.21 0 6 1.54 3 6 1.64 6 6 1.26 0
(simulated)
200 mg/dL ethanol 10 1.34 0 10 1.78 8 10 1.95 13 10 1.48 0
(simulated)
300 mg/dL ethanol 15 1.44 0 15 1.92 11 15 2.14 16 15 1.72 8
(simulated)
*Time (in hours) from end of continuous infusion to time of maximum clearance ration.
†Maximum clearance ratio (the maximum NAPQI formation clearance measured at any time during or after the ethanol infusion, [CL(t)], divided by the value
obtained with 5% dextrose in water infusion, [CL0]) at Tmax.
‡Time period (in hours) over which the clearance ratio is >1.5 (ie, NAPQI formation clearance enhanced by 50%).
§Simulated ethanol infusion for 6 hours, every 24 hours, over a period of 8 or more days. The elimination of ethanol was calculated with use of literature parameters
for Vmax and Km.30
For a 70-kg person, the total ethanol dose infused
during our protocol (1.58 mL/kg) corresponds roughly
to that in a standard 750-mL bottle of wine, six 12-
ounce cans of beer, or 9 ounces of 80-proof liquor. Our
data suggest that on the morning after such exposure,
ingestion of two extra-strength acetaminophen tablets
(1.0 g) would generate, on average, an amount of
NAPQI expected from a 1.24-g dose. Any additional
acetaminophen taken later would be subjected to
declining induction. According to established criteria,31
an adult without identifiable risk factors (ie, fasting,
ethanol, or liver disease) must consume at least 7.5 g
acetaminophen as a single dose to be at risk for liver
injury. Our data therefore suggest that the maximum
daily recommended dose of acetaminophen (4 g/day)
can be safely consumed by healthy adults after inges-
tion of the amount of ethanol administered in our study.
Ethanol is, of course, consumed in higher amounts,
often on a daily basis. Higher ethanol exposures were not
studied for ethical reasons. However, given the agreement
between model-based simulation, our experimental data
(Table II), as well as published data,14 and previous suc-
cess with modeling the isoniazid-acetaminophen interac-
tion in humans,22 we simulated other scenarios of com-
bined ethanol and acetaminophen use. As seen in Table
II, the simulated peak increases in NAPQI formation were
generally modest. For example, the model suggests that
nightly (“intermittent”) ingestion of the amount of ethanol
administered in our study would produce only a minimal
increase in NAPQI production (1.26) over that observed
after single intake (1.21). Even an individual who has a
blood ethanol level of 300 mg/dL for 200 hours (corre-
sponding to steady consumption of greater than 50 bot-
tles of wine over 8 days) would experience on average
only a 2.1-fold enhancement of NAPQI formation. This
increase in NAPQI formation would be the equivalent of
doubling the acetaminophen dose actually consumed.
These simulations should be interpreted cautiously
at present for several reasons. First, the magnitude and
timing of the interaction that we observed were slightly
underpredicted by the model simulation. Although the
predicted peak increase in CL(t)/CL0 produced after
our 6-hour ethanol infusion is close to what was actu-
ally observed (Table II), the model predicted the peak
would occur 6 to 7 hours after discontinuation of the
ethanol infusion, whereas the acetaminophen dose was
not given until 8 hours after the infusion was stopped.
In addition, the production of NAPQI occurs over sev-
eral hours and not just at the peak acetaminophen con-
centration. Further contributing inductive and inhibitory
effects of the ethanol metabolite acetaldehyde were not
taken into account in the simulations.
The simulations and estimates of NAPQI formation
(Table II) also assume that CYP2E1 induction by ethanol
occurs only through enzyme stabilization. At blood
ethanol levels >250 mg/dL, in some species de novo syn-
thesis of CYP2E1 protein increases through messenger
ribonucleic acid (mRNA) stabilization,32-34 increased
translation efficiency, or both.35 In addition, an increase
in CYP2E1 mRNA in liver biopsy specimens from per-
sons with chronic alcoholism has been reported.36,37 Any
induction of CYP2E1 by acetaldehyde or increased de
novo synthesis would have a multiplying effect on the
enhanced NAPQI formation estimates in Table II. How-
ever, the maximal twofold increase in NAPQI formation
predicted from our model agrees well with the twofold
elevation in mean chlorzoxazone 6-hydroxylation activ-
ity (a selective in vivo probe of CYP2E1 activity)
reported in persons with severe chronic alcoholism when
that activity was measured at least 12 hours after the last
ingestion of alcohol.5
In addition to its effects on CYP2E1, ethanol may
deplete hepatic glutathione38 and possibly reduce glu-
tathione transport into mitochondria (a critical hepato-
cellular glutathione pool),39 enhancing cell sensitivity
to the damaging effects of NAPQI. Other concomitant
factors not directly related to ethanol may also enhance
susceptibility to acetaminophen hepatotoxicity. Pro-
longed fasting and long-term treatment with acet-
aminophen, which could deplete hepatic glutathione,
3′-phosphoadenosine-5′-phosphosulfate, and uridine
5′-diphosphate glucuronic acid,40 and obesity, which
could increase CYP2E1 activity41 and cause nonalco-
holic steatohepatitis,42 may exacerbate the hepatocel-
lular response to acetaminophen attributable to
CYP2E1 induction by ethanol alone. When concomi-
tant risk factors are coupled with circumstances in
which patients could have a significant increase in
NAPQI production, then the dose of acetaminophen
may have to be reduced. This view does not mean that
acetaminophen should never be taken by the repeated
consumer of large amounts of ethanol. Alternative anal-
gesics (eg, nonsteroidal anti-inflammatory drugs) carry
their own risks, some of which (gastritis and hemor-
rhage) can be exacerbated by alcohol abuse.43
We conclude that ethanol can increase susceptibility to
acetaminophen-induced liver toxicity in healthy adults.
The magnitude of the increase in risk is a function of the
amount of ethanol consumed, the duration of ethanol
ingestion, and the relative timing of acetaminophen and
ethanol ingestions. When ethanol is in the body, it protects
the liver from toxicity by diminishing the production of
NAPQI. However, shortly after the elimination of ethanol
from the body, susceptibility to toxicity may be enhanced.
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